NCIC CLINICAL TRIALS GROUP

BREAST

DISEASE SITE COMMITTEE MEETING

AGENDA

Delta Chelsea Hotel, Toronto, Ontario
Saturday, May 3, 2008 - 8:30 a.m. - 4:15 p.m.
Room: Mountbatten Salon

Co-Chairs: T. Whelan, K. Gelmon
Past Co-Chair: K. Pritchard

8:30 a.m.  WELCOME

OPEN TRIALS
MA.17R  L. Shepherd
MA.22  M. Trudeau
MA.27, MA.27B, MA.27D  J. Pater
MA.29  M. Trudeau
MAP.1, MAP.2, MAP.3  H. Richardson / E. Winquist

CTSU TRIALS – OPEN AND CLOSED
MAC.1 (CALGB 49907/CTSU 49907) (Elderly) - update  D. Grenier
MAC.3 (ECOG E2100) (Taxol +/- Avastin)  T. Shenkier
MAC.4 (IBCSG 24-02/SOFT)  B. Walley
MAC.5 (IBCSG 25-02/TEXT)  B. Walley
MAC.7 (SWOG S0226) (Al vs Al + F)  T. Vandenberg
MAC.8 (NSABP 37)  M. Clemons
MAC.9 (SWOG S0307) Bisphosphonate  M. Clemons
MAC.11 (SWOG 0221) (Adjuvant Chemo in high risk)  J. Latreille
MAC.12 TAILORx  K. Pritchard
MAC.13 ALTTO  K. Pritchard

10:30 a.m.  COFFEE BREAK

10:45 a.m.  NEW / PENDING TRIALS
MA.30 - Anastrozole +/- Faslodex, Adjuvant  K. Pritchard
MA.31 - Lapatinib vs trastuzumab in Metastatic Breast Cancer  K. Gelmon
MA.33 - (TROG 07.01) Non-low Risk DCIS of Breast  I. Olivotto
MA 32 - Metformin  P. Goodwin

12:00 p.m.  LUNCH
1:30 p.m. **TRIAL PROPOSALS**

ECOG Avastin Trial  
SNAC2: Surgical Proposal  
BRCA Proposal  
Neoadjuvant Abraxane Proposal  

2:15 P.M. **CLOSED TRIALS**

MA.5 – Triple Negatives  
MA.21 Triple Negatives  
MA.21 –Manuscript and second analysis  
MA.12 – manuscript  
MA.14 – Presentation – Final Analysis  
MA.17, MA.17L, MA.17B  
MA.20 - Update  
MA.24 - and Trans HERA – Substudies and next analysis  
MA.26 - Observation +/- Tam vs. Rt +/- Tam, Good Risk DCIS  

3:15 p.m. **IND TRIALS**

IND.163  

3:30 p.m. **Update from IND Retreat**

Outcome of IND/Breast Strategic Retreat for Priority Targets  

3:40 p.m. **Update from Pharmacogenomics Meeting**

G. Liu / K. Gelmon  

3:55 p.m. **Tissue / Serum Collections / Correlative Trials**

- Microenvironment and breast cancer  
- Biomarker Meeting: Bruges  

4:15 p.m. **Adjournment**

4:15 p.m. **Brief Executive Meeting**